

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

FURTHER SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE COMPANY DATED 26 APRIL 2023

References are made to the circular of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) dated 26 April 2023 (the “**Circular**”) and the announcement of the Company dated 3 May 2023 (the “**Announcement**”) in relation to, among others, the proposed amendments to the articles of association of the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the meanings as those defined in the Circular and the Announcement.

The Company would like to further supplement that the Proposed Amendments in respect of Articles 1 (save for the amendment of the third paragraph regarding the change of name of shareholders), 17 (save for the amendment of the third paragraph as a result of preceding amendment), 48, 61, 63, 67 (save for the additional paragraph thereunder), 79, 85, 86, 87, 88, 89, 90, 91, 92 and 100 will take effect upon the consequential amendments to the Listing Rules in light of the regulation changes in the PRC becoming effective.

Save as disclosed above, all other information in the Circular and the Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Circular and the Announcement.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, 9 May 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.